Metozolv ODT patient profiles

Patients with diabetic gastroparesis and refractory GERD

We would like you to meet several hypothetical patients to help give you an idea of who might be right for Metozolv ODT.

Kyle

34-year-old entrepreneur
Unsuccessful GERD treatment; tried increasing PPI dosage and implementing lifestyle changes
Maintains a rigorous business travel schedule
Often eats whatever is most convenient
Doesn’t always have access to fluids to take with medication

See how Metozolv ODT can help a patient like Kyle

Gloria

54-year-old judge
Diagnosed with type 1 diabetes 13 years ago
Has diabetic gastroparesis
Presiding over hearings and trials often delays her from taking her medication
Would like a more convenient dosage form of metoclopramide so she can better maintain compliance

See how Metozolv ODT can help a patient like Gloria

Sal

47-year-old chef
Has diabetic gastroparesis
Has an appetite for new and interesting cuisine
Tired of the fullness and nausea brought on immediately after eating only a small amount of food
Because of his work schedule and late hours, he is often noncompliant with current metoclopramide therapy

See how Metozolv ODT can help a patient like Sal

Discover the benefits of Metozolv ODT Learn answers to patients' frequently asked questions about Metozolv ODT Access additional disease information or tools for your practice

Reference: 1. METOZOLV ODT [package insert]. Morrisville, NC: Salix Pharmaceuticals, Inc; 2009.

IMPORTANT SAFETY INFORMATION

Treatment with metoclopramide can cause tardive dyskinesia, a serious movement disorder that is often irreversible. The risk of developing tardive dyskinesia increases with the duration of treatment and the total cumulative dose.
Metoclopramide therapy should be discontinued in patients who develop signs or symptoms of tardive dyskinesia. There is no known treatment for tardive dyskinesia. In some patients, symptoms may lessen or resolve after metoclopramide treatment is stopped.
Treatment with metoclopramide for longer than 12 weeks should be avoided in all but rare cases where therapeutic benefit is thought to outweigh the risk of developing tardive dyskinesia.

METOZOLV™ ODT (metoclopramide HCl) is indicated as short-term therapy for adults with symptomatic, documented gastroesophageal reflux disease (GERD) who fail to respond to conventional therapy and for the relief of symptoms associated with acute and recurrent diabetic gastroparesis (diabetic gastric stasis) in adults. Therapy should not exceed 12 weeks in duration. METOZOLV ODT is contraindicated in patients with intestinal obstruction, hemorrhage, or perforation; pheochromocytoma; known sensitivity or intolerance to metoclopramide; epilepsy; or are receiving concomitant medications with extrapyramidal reactions. METOZOLV ODT should be used with caution in patients showing acute dystonic reactions, drug-induced Parkinsonism, or other extrapyramidal symptoms; neuroleptic malignant syndrome; with a prior history of depression; hypertension; congestive heart failure and ventricular arrhythmia. Patients may experience withdrawal symptoms after stopping the use of METOZOLV ODT.

In clinical studies, the most frequently reported adverse events (≥2% occurrence) were headache, nausea, fatigue, somnolence, and vomiting.

Please see accompanying full Prescribing Information for Metozolv ODT, including BOXED WARNING.